News & Updates

Patients with mild-to-moderate ulcerative colitis (UC) can achieve deep remission with multidonor faecal microbiota transplantation (FMT) and anti-inflammatory diet, according to an open-label trial. Furthermore, remission can be sustained with anti-inflammatory diet over 1 year.

Switching from intravenous to subcutaneous infliximab appears to be safe and well-accepted, resulting in a reduced risk of relapse in some inflammatory bowel disease (IBD) patients, according to data from the REMSWITCH study.

Patients with nonalcoholic fatty liver disease (NAFLD) who take probiotics, prebiotics, or synbiotics (PPS) may have better energy metabolism, according to a recent study.